Description

Enhertu 100mg injection (Trastuzumab deruxtecan) Uses, Side Effects, Dosage & Price in Pakistan

Enhertu 100mg injection (Trastuzumab deruxtecan) is a prescription anticancer medicine used to treat selected cancers with specific HER2 characteristics. It is a HER2-directed antibody-drug conjugate (ADC) that combines HER2-targeted therapy with a topoisomerase inhibitor payload.

Each single-dose vial contains 100mg of trastuzumab deruxtecan as a lyophilized powder for intravenous infusion. Enhertu is not a medicine for self-administration and must be prepared and given by trained healthcare professionals.

Enhertu has established roles in several breast cancer settings and is also used in selected patients with HER2-mutant non-small cell lung cancer (NSCLC), HER2-positive gastric or gastroesophageal junction cancer, and certain HER2-positive unresectable or metastatic solid tumors.

Patients searching for Enhertu 100mg injection in Pakistan can contact Impo Medic to inquire about current availability, price, and sourcing information.

Enhertu 100mg injection (Trastuzumab deruxtecan) Used

Enhertu is used for specific cancers selected according to tumor type, HER2 status, previous treatment, and disease stage.

Current prescribing information includes uses in selected patients with:

• HER2-positive breast cancer
• HER2-low and HER2-ultralow metastatic breast cancer
• HER2-mutant unresectable or metastatic non-small cell lung cancer
• HER2-positive locally advanced or metastatic gastric or gastroesophageal junction cancer
• Certain HER2-positive unresectable or metastatic solid tumors

Enhertu also has roles in selected HER2-positive early breast cancer settings. The exact eligibility criteria vary considerably between indications.

For this reason, HER2 or HER2-mutation testing and specialist oncology assessment are important before treatment is selected.

Enhertu should never be started solely because a cancer is suspected to involve HER2. The oncologist must determine whether the patient’s tumor and treatment history match an approved or otherwise clinically appropriate treatment setting.

How Does Enhertu 100mg Injection Work?

Enhertu is an antibody-drug conjugate designed to target HER2, a protein that can be expressed at increased levels or otherwise play an important role in certain cancers.

The trastuzumab component recognizes and binds to HER2 on tumor cells. After binding, the medicine is internalized and its linker is cleaved, releasing the deruxtecan component.

Deruxtecan inhibits topoisomerase I, an enzyme involved in DNA replication. This causes DNA damage and can ultimately lead to cancer-cell death.

This targeted delivery approach allows a potent anticancer payload to be directed toward HER2-expressing cancer cells, although normal tissues can also be affected and serious adverse reactions can occur.

Enhertu 100mg Injection Dosage

Enhertu dosage depends on the cancer being treated.

For many approved indications, including several breast cancer settings, HER2-mutant NSCLC and certain HER2-positive solid tumors, the recommended dose is generally:

5.4mg/kg by intravenous infusion once every 3 weeks.

For HER2-positive locally advanced or metastatic gastric or gastroesophageal junction cancer, the recommended dose is generally:

6.4mg/kg intravenously once every 3 weeks.

Treatment duration depends on the specific indication. In metastatic settings, therapy is often continued until disease progression or unacceptable toxicity, while some early breast cancer regimens have a defined number of treatment cycles.

These figures are provided for medicine information only. Patients must never calculate or determine their own Enhertu dose.

How Is Enhertu Injection Given?

Enhertu is given as an intravenous infusion by trained healthcare professionals.

The first infusion is generally administered over approximately 90 minutes. If the first infusion is well tolerated, subsequent doses can generally be administered over approximately 30 minutes.

Enhertu should not be administered as an intravenous push or bolus.

The medicine is highly emetogenic, meaning it can cause significant nausea and vomiting. Preventive anti-nausea treatment is therefore normally administered according to the patient’s oncology treatment protocol.

Enhertu 100mg Injection Side Effects

Like other cancer treatments, Enhertu 100mg injection can cause side effects.

Common or clinically important adverse effects may include:

• Nausea
• Vomiting
• Fatigue
• Reduced appetite
• Constipation or diarrhea
• Hair loss
• Anemia
• Reduced white blood cells
• Reduced neutrophils
• Reduced platelets
• Musculoskeletal discomfort

The side-effect profile varies according to the cancer being treated and whether Enhertu is given alone or as part of a combination treatment.

Patients should report new or worsening symptoms to their oncology team promptly.

Important Warning: Interstitial Lung Disease and Pneumonitis

One of the most important risks associated with Enhertu is interstitial lung disease (ILD)/pneumonitis.

Cases can be severe, life-threatening, or fatal.

Patients should immediately report symptoms such as:

• New or worsening cough
• Shortness of breath
• Difficulty breathing
• Fever
• Other new respiratory symptoms

Suspected ILD requires prompt medical investigation.

For symptomatic Grade 2 or higher ILD/pneumonitis, current prescribing information calls for permanent discontinuation of Enhertu and prompt systemic corticosteroid treatment.

Because early recognition can be important, patients should never wait for respiratory symptoms to become severe before contacting their oncology team.

Neutropenia and Blood Cell Changes

Enhertu can reduce neutrophils and other blood-cell counts.

A complete blood count (CBC) is generally checked before treatment starts, before each dose, and additionally when clinically necessary.

Severe neutropenia can increase the risk of infection. Patients should promptly report fever, chills, sore throat, or other symptoms that could indicate infection.

Depending on severity, treatment may need to be temporarily interrupted or the dose reduced.

Heart Function and Enhertu

HER2-directed therapies can affect heart function in some patients.

Enhertu has been associated with left ventricular dysfunction, including decreases in left ventricular ejection fraction (LVEF).

Heart function should generally be assessed before starting treatment and monitored at appropriate intervals during therapy.

Tell your oncology team about existing heart disease or symptoms such as unusual shortness of breath, swelling of the legs, rapid weight gain, or significant fatigue.

Pregnancy and Embryo-Fetal Toxicity

Enhertu carries an important warning regarding embryo-fetal toxicity.

Exposure during pregnancy can cause harm to an unborn baby. Patients who can become pregnant should follow their oncology team’s recommendations regarding pregnancy testing and effective contraception.

Men with partners who can become pregnant may also need effective contraception for the recommended period after their final dose.

Patients who become pregnant or believe they may be pregnant during treatment should contact their healthcare professional promptly.

Monitoring During Enhertu Treatment

Patients receiving Enhertu require regular oncology monitoring.

Depending on the patient’s condition, monitoring can include:

• Complete blood counts
• Respiratory symptoms and lung assessment
• Heart function, including LVEF
• Treatment response
• Liver and kidney function when clinically appropriate
• Nausea and vomiting
• Other treatment-related adverse effects

Imaging may also be performed periodically to assess cancer response or progression.

Close monitoring allows the oncology team to identify complications early and determine whether treatment should continue, be interrupted, reduced, or discontinued.

Enhertu 100mg Injection Price in Pakistan

The Enhertu 100mg injection price in Pakistan can vary considerably according to supplier, availability, import costs, currency fluctuations, and other market factors.

As a specialized biologic oncology medicine, Enhertu can be expensive, and current pricing should always be confirmed at the time of inquiry rather than relying on an outdated amount found online.

Patients and caregivers can contact Impo Medic to ask about the latest Enhertu 100mg injection price in Pakistan and available sourcing options.

For high-value oncology medicines, authenticity, correct storage, and appropriate supply-chain handling should be prioritized rather than selecting a product solely on the basis of the lowest quoted price.

Enhertu 100mg Injection Availability in Pakistan

Enhertu 100mg injection availability in Pakistan may vary because advanced oncology medicines are not necessarily stocked by every pharmacy or medicine supplier.

Patients prescribed Enhertu can contact Impo Medic to inquire about current availability and sourcing information in Pakistan.

Before purchasing, customers should verify the exact medicine name, 100mg vial strength, packaging, batch and expiry details, and other relevant product information.

Because Enhertu is a biologic oncology medicine requiring appropriate handling, storage and supply-chain conditions are especially important.

How to Buy Enhertu 100mg Injection in Pakistan

Patients and caregivers looking to buy Enhertu 100mg injection in Pakistan can contact Impo Medic for information regarding current availability, price, and sourcing.

When making an inquiry, provide the complete product details:

Enhertu 100mg injection (Trastuzumab deruxtecan)

Enhertu is a prescription anticancer medicine and should only be obtained for use under an oncologist’s treatment plan.

Impo Medic can assist with product availability and sourcing information, while the decision to start Enhertu, determine the dose, modify treatment, or discontinue therapy must remain with the treating oncology team.

Why Choose Impo Medic?

Impo Medic helps patients and caregivers in Pakistan search for specialty, imported, prescription, and oncology medicines that may be difficult to locate through routine pharmacy channels.

For Enhertu, patients can contact Impo Medic to inquire about Enhertu 100mg injection price in Pakistan, current availability, product details, and sourcing information.

Timely access, product authenticity, correct strength, and appropriate handling are particularly important with advanced cancer medicines. Impo Medic aims to make medicine availability information easier to access while encouraging patients to follow their oncologist’s treatment plan.

Storage and Handling

Enhertu requires appropriate pharmaceutical storage and professional handling.

The unopened medicine should be stored according to the conditions stated in its official product information and original packaging. Preparation and reconstitution should be performed by trained healthcare professionals using appropriate procedures.

Patients should not attempt to prepare, mix, store after reconstitution, or administer Enhertu themselves.

Frequently Asked Questions

What is Enhertu 100mg injection (Trastuzumab deruxtecan) used for?

Enhertu is a HER2-directed antibody-drug conjugate used for selected HER2-related cancers, including certain breast cancers, HER2-mutant NSCLC, HER2-positive gastric or GEJ cancer, and certain HER2-positive solid tumors. Exact eligibility depends on the cancer and treatment history.

Is Enhertu chemotherapy?

Enhertu is an antibody-drug conjugate rather than conventional standalone chemotherapy. It combines a HER2-targeting antibody with a topoisomerase I inhibitor payload that produces an anticancer effect.

How often is Enhertu given?

For many approved indications, Enhertu is administered once every three weeks. The exact dose and duration depend on the cancer being treated and the patient’s clinical situation.

What are the major side effects of Enhertu?

Potential effects include nausea, fatigue, vomiting, appetite changes, low blood-cell counts and hair loss. Important serious risks include ILD/pneumonitis, neutropenia and left ventricular dysfunction.

Can Enhertu affect the lungs?

Yes. Interstitial lung disease and pneumonitis are major recognized risks and can occasionally be fatal. New cough, shortness of breath, fever, or worsening breathing symptoms should be reported immediately.

Is Enhertu used only for breast cancer?

No. Although Enhertu has important breast cancer indications, it is also approved for selected HER2-mutant NSCLC, HER2-positive gastric/GEJ cancer, and certain HER2-positive solid tumors.

What is Enhertu 100mg injection price in Pakistan?

The price may vary according to current stock, supplier, import conditions, and currency changes. Contact Impo Medic for current Enhertu price and availability information in Pakistan.

Where can I buy Enhertu 100mg injection in Pakistan?

Patients and caregivers can contact Impo Medic for information about Enhertu availability and sourcing in Pakistan. The medicine should only be used under specialist oncology supervision.